Mesoblast MEOBF
NASDAQ MEOBF
$1.90 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Mesoblast (MEOBF) Non-Current Debt (2018)

Mesoblast's (MEOBF) quarterly Non-Current Debt came in at $61.2 million in Q3 2018, up 2.97% quarter-over-quarter from $59.4 million in Q2 2018.

Analysis

Mesoblast (MEOBF) Non-Current Debt (2018) Analysis & Trends

Mesoblast has disclosed Non-Current Debt across 1 years of filings, most recently posting $61.2 million for Q3 2018.

  • In Q3 2018, Non-Current Debt changed N/A year-over-year to $61.2 million; the TTM figure through Sep 2018 stood at $61.2 million (changed N/A YoY), while the FY2018 annual figure was $59.4 million, changed N/A from the prior year.
  • Non-Current Debt came in at $61.2 million for Q3 2018 at Mesoblast, up from $59.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $61.2 million in Q3 2018 to a low of $31.4 million in Q1 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - 586.20 Mn
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn -
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn 50.15 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn - 100.26 Mn
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn 93.88 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn 847.62 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn -
10 Mesoblast 246.02 Mn 143.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 61.16 Mn
Jun 30, 2018 59.40 Mn
Mar 31, 2018 31.42 Mn